Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy  by Anderson, Jeffrey L. et al.
lACC Vol. 17, No.6 
May 1991:1373-81 
REPORTS ON THERAPY 
1373 
Long-Term (2 Year) Beneficial Effects of Beta-Adrenergic Blockade 
With Bucindolol in Patients With Idiopathic Dilated Cardiomyopathy 
JEFFREY L. ANDERSON, MD, FACC, EDWARD M. GILBERT, MD, 
JOHN B. O'CONNELL, MD, FACC, DALE RENLUND, MD, FACC, 
FRANK YANOWITZ, MD, FACC, MARIANNE MURRAY, RN, MARIAN ROSKELLEY, BS, 
PATRICE MEALEY, RN, KIRK VOLKMAN, RN, DAVID DEITCHMAN, PHD, 
MICHAEL BRISTOW, MD, PHD, FACC 
Salt Lake City, Utah 
Beta-adrenergic blockade represents a promising therapeutic ap-
proach to idiopathic dilated cardiomyopathy. Bucindolol, a new 
beta-blocker, showed favorable effects in a short-term (3 month) 
trial in idiopathic dilated cardiomyopathy. To assess long-term 
response, 20 study patients (7 of 9 patients previously assigned to 
the placebo group and 13 of 14 patients previously assigned to 
bucindolol therapy) received long-term bucindolol therapy and 
were followed up for a mean of 23 ± 4 months (range 17 to 30). 
The mean patient age was 49 years (range 29 to 66) and the 
median duration of disease was 11 months (range 1 to 190). Ten 
patients were in functional class II and 10 were in class III; 15 
patients were men. 
At the end of the common follow-up time, all 20 patients were 
alive, 17 continued to receive bucindolol (mean dose 176 mg/day, 
range 25 to 200), and 2 underwent cardiac transplantation. Left 
ventricular ejection fraction increased from a baseline value of 
Congestive heart failure is a major and growing public health 
problem, only partly accounted for by aging of the popula-
tion (1). Once overt heart failure develops, prognosis is poor 
despite conventional medical therapies (2-4). Although the 
newer inotropic agents initially improve systolic function, 
they may not benefit long-term outcome (4-7). Vasodilator 
and converting enzyme inhibitor therapy contribute to im-
proved symptomatic and survival outcome (8,9). but long-
term prognosis continues to be poor after the 1st 2 years. 
Given the impact and poor prognosis 'of heart failure, the 
evaluation of new medical therapies is needed (5). 
Idiopathic dilated cardiomyopathy, although a less com-
mon cause of heart failure than ischemic heart disease, is 
being recognized increasingly in the general population. The 
proportion of younger patients «50 years old) is greater 
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25 ± 8% to 35 ± 13% (n = 19 pairs, p < 0.001). Functional class 
improved in 12, was unchanged in 5 and deteriorated in 3 (p = 
0.056). Exercise time was maintained (9.4 ± 3.1 versus 9.1 ± 3.5 
min, n = 19, P = NS), as was maximal oxygen uptake (19.2 ± 4.9 
versus 18.8 ± 5.7 mIlkg per min, n = 19, P = NS). 
Thus, long-term bucindolol therapy leads to substantial in-
creases in ejection fraction and to improved functional class while 
stable exercise performance is maintained. Also, similar or better 
ejection fractions and exercise times were observed after long-
term compared with short-term (3 months) therapy. Given these 
excellent results with respect to drug tolerance, survival rate and 
functional efficacy after approximately 2 years, long-term bucin-
dolol therapy deserves further evaluation in patients with heart 
failure, especially those with idiopathic dilated cardiomyopathy 
who are in functional classes II and III. 
a Am Coll CardioI1991;17:1373-81) 
among patients with this disease than among patients with 
ischemic heart disease. Therapy with beta-adrenergic block-
ing agents has been advocated as a potentially useful ap-
proach. but is still regarded as unconventional. Several 
reports 00-13) suggest that chronic beta-blockade. most 
often with the beta-1 selective agent metoprolol, may im-
prove hemodynamic and clinical function in patients with 
idiopathic dilated cardiomyopathy. However, data from 
controlled trials are limited 04-16), and some investigators 
07-19) have not shown a beneficial effect in short-term 
trials. These conflicting reports and the paradoxic nature of 
beta-blocker therapy for heart failure (20-22) suggest that 
additional controlled observations are needed before such 
treatment can be generally accepted and recommended. 
Although beta-blockers may exert adverse effects 
through their negative inotropic action (20-22), they also 
have potentially beneficial actions, including protection of 
the myocardium from damage by chronic, excessive cate-
cholamine stimulation, restoration toward normal of the 
down-regulated membrane beta-receptor density often seen 
in heart failure, reduction in the risk of potentially lethal 
ventricular arrhythmias and. possibly, beneficial effects on 
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substrate utilization and energy-sparing actions that may 
preserve myocyte viability (5,23-26). 
Bucindolol is anew, potent and nonselective beta-
blocking agent with mild, direct-acting or "nonspecific," 
vasodilator properties (27-29). The intrinsic sympathomi-
metic activity observed with bucindolol in animal models has 
not been found in laboratory studies in human myocardium 
(30). The agent is well tolerated by patients with idiopathic 
dilated cardiomyopathy when administered in small, gradu-
ally ascending doses (31), in part because of its vasodilating 
properties. 
In the first part of this study we measured the short-term 
effects of bucindolol (over 90 days versus placebo) (31). In 
the present study we measured and compared this initial 
response with response during long-term (2 year) mainte-
nance therapy. 
Methods 
Study objectives. The primary objective of the study was 
to establish and compare the effects of long-term bucindolol 
therapy (after a mean of approximately 2 years) on clinical 
symptoms and left ventricular function at rest and during 
exercise with effects of short-term (3 month) therapy with 
placebo or bucindolol. Patient status was assessed as of 
November 1988, the final end point for follow-up evaluation. 
A secondary objective was to evaluate the continued toler-
ance and safety of bucindolol in a patient population with 
idiopathic dilated cardiomyopathy and symptomatic conges-
tive heart failure. The hypothesis of the study was that the 
initial beneficial responses in ejection fraction and functional 
capacity, observed after 3 months (31). would be maintained 
or augmented over a 2 year follow-up period. 
Patient eligibility. Consenting patients presenting to the 
heart failure clinic were screened for the study. To qualify 
for study entry, patients were required to have a diagnosis of 
idiopathic dilated cardiomyopathy, confirmed echocardio-
graphically, in association with symptomatic but clinically 
stable heart failure. Adults aged 18 to 80 years were ac-
cepted. Left ventricular ejection fraction, determined by 
radionuclide ventriculography. was required to be <40%. 
Patients were required to be able to exercise for ;::::4 min but 
:::; 16 min with use of the modified Naughton treadmill proto-
col. Two baseline treadmill tests were performed and total 
exercise times were required to fall within 20% of each 
other. 
Exclusion criteria included known active myocarditis and 
a known secondary cause of cardiomyopathy such as coro-
nary artery disease, restrictive or hypertrophic disease. 
alcoholism, endocrine or autoimmune disease. Asthma or 
chronic obstructive pulmonary disease. which are contrain-
dications to beta-blockade, were also exclusion criteria. 
Unstable rhythm disorders. including symptomatic or sus-
tained ventricular tachycardia or advanced heart block or 
bradyarrhythmia, were also exclusions. Chronic alcoholism 
or drug abuse. significant noncardiac illness including renal 
lACC Vol. 17, No.6 
May 1991: 1373-81 
or hepatic dysfunction, and pregnancy or peripartum status 
were other exclusions. 
Permissible concomitant medications during the study 
included diuretics, digitalis glycosides, approved class I 
antiarrhythmic agents, nitrates and angiotensin-converting 
enzyme inhibitors, primarily captopril. Excluded medica-
tions were other beta-blockers, calcium channel blockers 
and antihypertensive or vasodilator medications other than 
captopril (or other converting enzyme inhibitors), nitrates 
and diuretics. 
The long-term assessment was made in 20 consecutive 
patients completing the short-term (90 day) study. Prior 
approval for both the short-term and the long-term studies 
was obtained from the Institutional Review Committee on 
Human Research, and each patient gave written informed 
consent before study entry. 
Serial tests of functional outcome. Serial functional as-
sessment included the following: 1) clinical history, physical 
examination and interval assessment of clinical status every 
2 months for the 1st year, then every 3 to 6 months; 2) 
laboratory and blood chemistry evaluation and electrocar-
diographic (ECG) testing at each visit; 3) radio nuclide ven-
triculography at baseline and at 3. 6 and 12 months, then 
every 6 to 12 months during long-term therapy (rest left 
ventricular ejection fraction formed the primary end point); 
and 4) a modified Naughton exercise test to tolerance, with 
measurement of maximal oxygen consumption, performed at 
the same time intervals as radionuclide ventriculography. 
Statistical analysis. Fisher's exact test was used to com-
pare characteristics of the two groups for discrete variables 
and Student's paired t test for continuous variables mea-
sured at baseline and during therapy. Control tests before 
the short-term study were used as baseline measures in 
patients assigned to the bucindolol group, and the last tests 
during placebo administration (at 3 months) before initiation 
of open label (long-term) bucindolol therapy were used as 
baseline measures in patients assigned to the placebo group. 
Differences between baseline (drug-free or placebo) and 
treatment variables for each group were compared with one 
sample or paired Student's t tests. A Student's unpaired t 
test was used to make intergroup comparisons of difference 
scores. Values are expressed as mean values ± SD in the 
text and ± SEM in tables and figures, unless otherwise 
indicated. Differences were considered significant at p < 
0.05 for changes in the primary end point (rest ejection 
fraction) and conditionally significant at p < 0.05 for the 
other variables. 
Results 
Summary of short- and long-term patient flow and patient 
characteristics (Fig. 1). Twenty-four subjects entered the 
short-term placebo-controlled study. and 23 (96%) tolerated 
an initial test dose of bucindolol (12.5 mg every 12 h for 2 to 
3 doses) during clinical and hemodynamic monitoring; these 
23 entered the controlled trial and received a random treat-
lACC Vol. 17, No.6 
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Figure 1. Patient (PT) flow diagram for short-term and 
long-term treatment studies. Rx = treatment. 
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Entry Into Study After Qualifying: 24 Pts. 
~ Intolerance to I test dose: 1 Pt. 
Entry Into Short-Term 
placebo-Controlled Study: 23 Pts. 
Bucindolol: 14 Pts. 
Completion of 
Withdrawal 
(Deterioration, Pulmonary 
Embolus): 1 Pt. 
Short-Term Study: 13 Pts. 
Placebo: 9 Pts. 
Completion of 
Short-Term Study 
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fiJeterioration: 1 Pt. I Death: 1 Pt. 
13 Pts. 7 Pts. 
ment allocation to bucindolol or placebo, on the basis of a 
3: 2 randomization schedule. (The unequal randomization in 
favor of bucindolol was used to gain additional early expe-
rience with drug effects [safety, efficacy] in the cardiomyop-
athy patient group.) Fourteen patients were randomized to 
and entered the bucindolol treatment arm and 9 entered the 
placebo treatment arm. During or at the end of the 3 month 
short-term (placebo-controlled) phase, three patients 
dropped out. Two of these patients were in the placebo 
treatment group; one of these two patients died and the other 
showed clinical deterioration and was believed to be a poor 
candidate for initiating beta-blocker therapy. One bucin-
dolol-treated patient showed deterioration and underwent 
cardiac transplantation. The other 20 patients (83% of the 
initial cohort) entered the long-term treatment and evalua-
tion phase. 
Characteristics of the 20 study patients followed up 
long-term are summarized in Table 1 and compared with 
those of the entire 24 patient cohort. The average patient age 
was 49 years (range 29 to 66). Fifteen (75%) were men. The 
median disease duration was 11 months (range 1 to 190). Ten 
were in New York Heart Association functional class II and 
10 were in class III. Left ventricular ejection fraction aver-
Entry Into 
Long-Term Therapy: 20 Pts. 
I Withdrawal (Deterioration): 3 Pts_ Oral inotrope Rx: 1 Pt. Transplantation: 2 Pts_ 
Continuation of Bucindolol 
at End-Follow-Up: 17 Pts. 
Table 1. Patient Characteristics at Entry Into Study 
Clinical characteristics 
No. of patients 
Age (yr)* 
Male/female ratio 
NYHA functional class* 
LV ejection fraction (%)* 
Cardiac index (liters/min per m2)* 
Pulmonary wedge pressure (mm Hg)* 
Concomitant medications 
Diuretic (no.: %) 
Digoxin (no.: %) 
ACE inhibitor (no.: %) 
Antiarrhythmic (no.: %) 
Warfarin (no.: %) 
Bucindolol dose (mg/day)* 
Long-Term 
Phase 
20 
49.4 ± 10.9 
(29-66) 
15/5 
2.5 ± 0.5 
24.9 ± 7.6 
00-39) 
2.15 ± 0.40 
16.1 ± 8.8 
18: 90% 
15; 75% 
13: 65% 
5: 25% 
9: 45% 
176 ± 58 
(25-200) 
Short-Term 
Phase 
24 
51.0 ± 10.7 
(29-66) 
16/8 
2.6 ± 0.6 
23.4 ± 8.0 
(10-39) 
2.24 ± 0.49 
15.7 ± 8.5 
22: 92% 
21: 88% 
17: 71% 
7; 29% 
15; 63% 
170 ± 81 
(25-200) 
*Mean value ± SD (range). ACE = angiotensin-converting enzyme; LV = 
left ventricular: NYHA = New York Heart Association. 
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aged 24.9% (range 10% to 39%). Baseline invasive evalua-
tion during standard medical therapy revealed an average 
cardiac index of 2.15 liters/min per m2 and a pulmonary 
wedge pressure of 16.1 mm Hg. Characteristics of the entire 
group of 24 patients initially entered were similar to those of 
the 20 patients evaluated beyond 3 months. 
Concomitant medications. Concomitant medications used 
to treat heart failure are summarized in Table 1. Of the 20 
patients evaluated long-term, 90% were receiving diuretics, 
75% digitalis and, notably, 65% an angiotensin-converting 
enzyme inhibitor, primarily captopril; 25% were receiving a 
class I antiarrhythmic agent for symptomatic arrhythmias 
and 45% long-term anticoagulation with warfarin. Concom-
itant therapy for the long-term and short-term patient co-
horts was similar. 
The average dose of bucindolol given long-term was 
176 mg/day, usually divided into 2 equal doses. Seventeen 
patients received the full dose of 100 mg twice daily and 
three received doses of 25 or 50 mg/day. Average doses of 
bucindolol were similar during long-term and short-term 
therapy. The maintenance dose of bucindolol was achieved 
by gradual titration, beginning with 12.5 mg twice daily and 
progressing at no less than 1 week intervals, as tolerated, to 
25,50 and, finally, 100 mg twice daily during careful moni-
toring. Dose titration with bucindolol occurred during the 
blinded, short-term phase for patients randomized to active 
therapy and during the open label, long-term phase for 
patients who had received placebo during the short-term 
phase. 
Duration of follow-up and status of patients treated long-
term. Duration of follow-up after initiation of bucindolol 
therapy in the 20 patients followed up after 3 months 
averaged 23 ± 4 months (range 17 to 30). Actual duration of 
therapy, adjusted for the four patients who discontinued 
bucindolol temporarily or permanently, averaged 21 months 
(range 1.5 to 30). All 20 patients entered into the long-term 
study were alive at the common study end point (November 
1988). Seventeen (85%) were continuing on bucindolol ther-
apy, one patient with symptoms of progressive heart failure 
discontinued bucindolol therapy and received an oral inotro-
pic agent and two with deterioration in function underwent 
successful cardiac transplantation. 
Summary of short-term benefit. As previously reported 
(31), bucindololled to substantial short-term improvement in 
rest left ventricular function. Table 2 summarizes results for 
noninvasive functional variables after both short-term (3 
month) and long-term (mean 16 to 23 months) therapy. In the 
short-term, rest left ventricular ejection fraction improved 
substantially with bucindolol over that at baseline and with 
placebo therapy. After 3 months, ejection fraction had 
increased by 8.7 percentage points, or about 34% over 
baseline. Ejection fraction during maximal exercise also 
improved substantially (by an average of 5.4 points com-
pared with baseline). These changes in ejection fraction were 
associated with improvement (by about Y3 class) in func-
tional class. Heart rate at rest decreased by 15 beats/min, but 
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mean blood pressure was unchanged. Large reductions in 
maximal exercise heart rate were observed (by an average of 
37 beats/min), attesting to the substantial beta-blocking 
activity of bucindolol in the doses given. However, both 
maximal exercise blood pressure and treadmill time were 
maintained (only insignificant reductions). 
Cardiac index increased in the bucindolol-treated patients 
but decreased in the placebo group; pulmonary wedge 
pressure was substantially lower after bucindolol but in-
creased during 3 months of placebo treatment; stroke work 
index showed an increase of almost 50% after bucindolol and 
quantitative heart failure symptom score decreased by al-
most 40% in the treated group but was unchanged or 
increased in the placebo group, as previously reported (31). 
We found that improvement during the 1st 3 months of 
open label bucindolol therapy in patients previously given 
placebo (crossover group) was similar to the response of the 
group assigned to blinded bucindolol therapy during the 
short-term phase (p = NS for all intergroup comparisons of 
change scores), further confirming the drug-related nature of 
the changes (Table 3). 
Long-term changes in functional class and ejection fraction 
(Table 2, Fig. 2 and 3). At the end of the follow-up period, 
New York Heart Association functional class had improved 
from a mean of 2.6 to 2.0 among the 18 patients with paired 
assessments (p = 0.012, Wilcoxon signed rank test). (Data 
from the two patients who had undergone transplantation 
and were in functional class I were censored.) To account for 
the two patients who underwent transplantation because of 
clinical deterioration, an imputed analysis (worst case sce-
nario) was performed, assigning a functional class of IV to 
these two patients at the end of follow-up: the functional 
class of the entire group then averaged 2.2, representing a 
strong beneficial trend compared with baseline (p = 0.056, 
Wilcoxon signed rank test, n = 20 pairs). Individually, 12 
patients showed an improvement in functional class, 5 
remained in the same class and 3 showed deterioration 
(including the 2 who underwent transplantation) during 
follow-up. 
Paired left ventricular ejection fraction information was 
available for 19 of the 20 patients (1 patient dropped out of 
therapy early and underwent transplantation). In these 19, 
ejection fraction at last assessment at a mean of 16.5 months 
averaged 35 ± 13%, compared with a baseline value of 25 ± 
8%, representing a highly significant 40% improvement over 
baseline (Fig. 2). To account for the three patients whose 
condition deteriorated and who stopped bucindolol during 
follow-up, an imputed analysis was also performed. An 
ejection fraction of "0" was assigned at end of follow-up to 
these three patients, two of whom underwent transplantation 
and one of whom changed to alternative therapy during the 
long-term study. A beneficial overall effect on change in 
ejection fraction was still shown for the entire group when 
values at end of follow-up were compared with the pretreat-
ment baseline study (p = 0.025, Wilcoxon signed rank test, 
n = 20 pairs). 
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Table 2. Comparative Functional Changes After Short-Term (90 day) and Long-Term Therapy for Parallel, Blinded and Baseline-
Controlled Study Groups 
Therapy Group 
Short-Term, Baseline and Parallel (randomized, blinded) 
Placebo Controlled 
Long-Term, Baseline 
Controlled§ 
Bucindolol (blindedll 
plus open label) Placebo 
Measure (n = 9) 
p Value 
Placebo vs. Bucindolol 
Bucindolol (blinded) 
(n = 14) (n = 20) 
Left ventricular EF (%) 
Baseline 21.1 ± 2.8 (9) 
A 3 months (n) 1.1 ± 1.5 (9) 
A End follow-up (n) 
Heart rate (beats/min) 
Baseline 105.0 ± 7.6 (9) 
A 3 months (n) -4.6 ± 3.4 (9) 
A End follow-up (n) 
Mean blood pressure (mm Hg) 
Baseline 86.7 ± 2.7 (9) 
A 3 months (n) -OJ ± 4.1 (8) 
A End follow-up (n) 
Functional class (NYHA) 
Baseline 2.7 ± 0.2 (9) 
A 3 months (n) o ± 0 
A End follow-up (n) 
Treadmill time (min) 
Baseline 7.27 ± 0.97 (9) 
A 3 months (n) 0.40 ± 0.47 (9) 
A End follow-up (n) 
Exercise left ventricular 
Baseline 23.1 ± 4.3 (8) 
A 3 months (n) -1.5 ± 1.4 (8) 
A End follow-up (n) 
Exercise heart rate (beats/min) 
Baseline 148.7 ± 7.7 (9) 
A 3 months (n) -0.4 ± 2.5 (9) 
A End follow-up (n) 
Exercise blood pressure (mm Hg) 
Baseline 90.6 ± 3.8 (9) 
A 3 months (n) 4.1 ± 2.4 (8) 
A End follow-up (n) 
0.023 
0.022 
0.865 
0.004 
0.28 
0.035 
<0.001 
0.063 
25.1 ± 1.8 (14) 
8.7 ± 203 (13)t 
97.1 ± 2.6 (14) 
-18.0 ± 3.8 (13):1: 
87.7 ± 3.9 (14) 
0.5 ± 2.5 (13) 
2.5 ± 0.1 (14) 
-0.4 ± 0.2* (14) 
9.54 ± 0.85 (14) 
-0.47 ± 0.57 (13) 
24.9 ± 2.8 (14) 
5.4 ± 2.2 (13)* 
160.4 ± 5.8 (14) 
- 37.4 ± 603 (1m 
98.6 ± 4.0 (14) 
-5.5 ± 3.5 (13) 
24.9 ± 1.7 (20) 
8.7 ± 1.7 (19)t 
9.7 ± 2.2 (19H 
96.1 ± 3.2 (20) 
-15.5 ± 3.1 (20)t 
-14.8 ± 3.3 (19)t 
88.2 ± 2.8 (20) 
OJ ± 2.1 (20) 
3.1 ± 2.6 (20) 
2.5 ± 0.1 (20) 
-OJ ± 0.1 (20)* 
-0.5 ± 0.2 (18)* 
9034 ± 0.69 (20) 
-0.42 ± 0.44 (19) 
-0.21 ± 0.42 (19) 
25.4 ± 2.6 (19) 
6.4 ± 2.0 (l5)t 
9.3 ± 1.9 (16)t 
158.0 ± 4.8 (20) 
- 36.7 ± 4.6 (19)t 
-38.5 ± 4.1 (19)t 
98.4 ± 3.2 (20) 
-5.0 ± 2.8 (19) 
-0.95 ± 3.1 '(20) 
All values are mean values ± SEM (n). *p < 0.05 versus baseline; single sample t test. tp < 0.01 versus baseline; single sample t test. :j:p < 0.001 versus 
baseline; single sample t test. §The off-therapy test performed just before initiation of active therapy with bucindolol was used as the baseline (i.e., the average 
of the two baseline tests for patients initially assigned to bucindolol, and the placebo test at 3 months for patients initially assigned to placebo). IIBlinded at 3 
months for 13 patients. EF = ejection fraction; P = placebo. A = change value (difference of treatment minus baseline value). 
Long-term changes in rest vital signs and exercise measures 
(Table 2, Fig. 3). Bucindolol therapy in the doses given did 
not significantly affect mean blood pressure but reduced 
heart rate at rest by 15 beats/min and maximal exercise heart 
rate by 39 beats/min at last follow-up compared with baseline 
values (Table 2). Exercise treadmill time, however, re-
mained constant, averaging 9.1 ± 3.5 min at the last fol-
low-up at a mean of 16.2 months, compared with a baseline 
value of 9.4 ± 3.1 min (n = 19 pairs, p = NS) (Fig. 3). In 
keeping with these treadmill time results, measurements of 
maximal oxygen consumption during therapy did not 
change. During the long-term follow-up period, maximal 
oxygen consumption averaged 18.8 ± 5.7 ml 02/kg per min, 
compared with 19.2 ± 4.9 at baseline (n = 19 pairs, p = NS). 
Time course of change in ejection fraction, treadmill time 
and other variables. To evaluate the long-term change in the 
major functional end points of ejection fraction and treadmill 
time beyond those of short-term (90 day) therapy, results 
after 3 months were compared with those at the last fol-
low-up test (mean 16 months). The individual paired re-
sponses (Fig. 4) reveal that ejection fraction showed addi-
tional increments, whereas paired treadmill times showed 
variable results but no overall change. 
Figure 5 shows the mean responses at baseline, 3 months 
and last follow-up (mean 16 months) in patients with serial 
studies. Treadmill time was maintained unchanged through-
out, averaging 9.2 min at baseline and 9.1 min at both 3 and 
16 months of therapy. For ejection fraction, the mean of 
1378 ANDERSON ET AL. 
LONG-TERM BUCINDOLOL FOR CARDIOMYOPATHY 
lACC Vol. 17, No.6 
May 1991:1373-81 
Table 3. Comparison of Change Scores in Noninvasive Variables After 3 Months of Bucindolol 
Therapy for Placebo-Crossover and Blinded Bucindolol Groups 
Variable Placebo-Crossover Blinded Bucindolol p Value" 
dEFr (% points) 8.83 ± 1.76 (6)t 8.69 ± 2.33 (l3)t 0.97 
dHRr (beats/min) -10.86 ± 5.3 (7) -18.0 ± 3.8 (l3):j: 0.29 
dBPr(mm Hg) -0.29 ± 4.2 (7) 0.54 ± 2.5 (13) 0.86 
dFC (I-IV) -0.21 ± 0.26 (7) -0.43 ± 0.17 (14)* 0.49 
dETT (min) -0.39 ± 0.77 (6) -0.47 ± 0.57 (13) 0.94 
dEFex (% points) 5.6 ± 2.4 (5) 5.4 ± 2.2 (13)* 0.96 
dHRex (beats/min) - 35.2 ± 5.8 (6)t - 37.4 ± 6.3 (l3):j: 0.83 
dBPex (mm Hg) -1.0 ± 4.9 -5.54 ± 3.5 (13) 0.47 
All values are mean values ± SEM (n). BP = blood pressure; d = change from baseline value to value at 3 
months; EF = ejection fraction; EIT = exercise treadmill time; FC = New York Heart Association functional class; 
HR = heart rate; subscripts ex and r = maximal exercise and rest study values. *p < 0.05; tp < 0.01; :j:p < 0.001 
versus baseline, single sample t test. "Unpaired t-test, intergroup comparison. 
serial observations increased from approximately 25% to 
31% at 3 months and further to 35.2% at a mean of 16 
months. At 3 months improvement over the baseline value 
was significant, and at the end of follow-up it was highly 
significant and the response was also significantly better than 
the response at 3 months for paired tests. 
Heart rate and blood pressure responses at long-term 
follow-up were similar to short-term response (Table 2). Rest 
and exercise heart rates remained significantly reduced, 
whereas rest and exercise blood pressures were unchanged 
and treadmill times were maintained. 
Correlation among individual change scores for functional 
class, ejection fraction, treadmill time and oxygen consump-
tion. A general correlation was found among individual 
change scores for functional class, ejection fraction, tread-
mill time and maximal oxygen consumption, comparing the 
baseline with the last follow-up study, using Spearman's 
rank correlation test (Table 4). Use of imputation for missing 
values improved the correlations. 
Discussion 
Summary of study results. In this assessment of long-
term (baseline-controlled) therapy after short-term (parallel, 
placebo-controlled) therapy of patients with idiopathic di-
Figure 2. Radionuclide resting left ventricular ejection fraction 
(LVEF) at baseline and at last follow-up test (mean, 16.5 months) 
during long-term bucindolol therapy for 19 matched pairs. 
40 
~ 30 
~ 
tt 20 
> 
-l 
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lated cardiomyopathy, bucindolol, a nonselective beta-
blocker with mild vasodilator effect was given in slow, 
carefully incremented doses. The drug was effective and 
generally well tolerated during a mean follow-up period of 
about 2 years. Seventeen of 20 patients entering long-term 
therapy (from an initial group of 24 patients studied short-
term) were continuing therapy at the end of our evaluation. 
In these patients, bucindolol therapy was associated with 
maintained or improved functional class and with large 
increases over baseline in mean ejection fraction. Ejection 
fraction, previously noted to be significantly improved at 3 
months, was further augmented during long-term therapy, 
last evaluated at a mean of 16 months. Bucindolol main-
tained (but did not increase) maximal exercise performance. 
Changes among functional indexes also showed a general 
correlation for individual patients. Of note, this improved 
and maintained functional outcome occurred after stabiliza-
tion on traditional medical therapy, including a converting 
enzyme inhibitor in two thirds of patients. 
Magnitude and mechanism of change in left ventricular 
ejection fraction. Improvement in ejection fraction was dra-
matic and documented to be bucindolol related during the 1 st 
3 months of therapy both by parallel comparisons with 
Figure 3. Maximal exercise treadmill time (ETT) at baseline and at 
last follow-up test (mean, 16.2 months) during long-term bucindolol 
therapy for 19 matched pairs. 
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* Mean, 16.2 mo. 
LonQterm * 
BUClndolol 
:j: p=ns vs baseline (N=19 pairs) 
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Figure 4. Paired individual responses (n = 19) for rest left ventric-
ular ejection fraction (LVEF) (top), and maximal exercise treadmill 
time (ETT) (bottom), comparing values after short term (3 months) 
and long term (mean 16 months) bucindolol (Buc.) therapy. 
placebo and by crossover comparisons with active drug. 
Subsequently, comparisons of long-term therapy with base-
line and 3 month values showed continued improvement. 
Although spontaneous (rather than drug-related) improve-
ments in left ventricular ejection fraction cannot be excluded 
after the 3 month study without an ongoing parallel control 
group, this possibility seems unlikely, given the known 
natural history of idiopathic dilated cardiomyopathy from 
other studies (2-4) and the adverse trend during the 1st 3 
months in our placebo-treated group (Tables 2 and 3). The 
magnitude of improvement in ejection fraction with bucin-
dolol is particularly noteworthy relative to the smaller 
changes shown for therapy with inotropic and vasodilator 
agents (including digoxin, captopril and milrinone) in recent 
trials (32,33). 
The present study does not reveal the mechanism of 
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Figure 5. Group responses (mean values ± SEM) for serial left 
ventricular ejection fraction (L VEF) (left) and serial exercise tread-
mill testing (ETT) (right) at baseline and during short-term (3 month) 
and long-term (mean 16 months) bucindolol (Buc.) therapy. 
bucindolol's benefit. Small increases in ejection fraction may 
occur secondary to reductions in heart rate, as stroke 
volume increases to maintain cardiac index. However, the 
changes observed here far exceed the effects that might be 
expected to occur as a result of the modest reductions in 
heart rate at rest. 
The recent hemodynamic study of Eichhorn et al. (34) 
confirms and extends the hemodynamic observations of our 
earlier study, based on short-term invasive indexes (31), and 
the current study, based on noninvasive indexes. In the 
study of Eichhorn et al. (34), bucindolol improved the 
end-systolic pressure-volume relation and the negative dif-
ferential of pressure versus time ( -dP/dt}-end-diastolic vol-
ume relation, two relatively load-independent measures of 
contractility, over 3 months of therapy. Myocardial relax-
ation also appeared to improve, as evidenced by an increase 
in -dP/dt at matched heart rates but lower preloads. Bucin-
dolol increased work load without a significant increase in 
oxygen consumption or decrease in afterload (34). Thus, 
bucindolol appears to improve myocardial contractility and 
relaxation without a concomitant increase in myocardial 
oxygen consumption, but further studies are needed to 
Table 4. Correlations Among Long-Term Change Scores for Selected Functional Measures* 
~FC 
~EF 
~ETT 
~FC 
-0.441, p = 0.058 
(-0.512, p = 0.021) 
-0.503, p = 0.021 
(-0.564, p = 0.010) 
-0.564. P = 0.012 
(-0.623. p = 0.003) 
~EF 
0.413, p = 0.079 
(0.492. p = 0.027) 
0.515. p = 0.024 
(0.584. p = 0.007) 
~ETT 
0.869, p = 0.001 
(0.885, p = 0.001) 
'Spearman's rank correlation test results applied to change scores (a) comparing initial baseline value with last 
follow-up study value for 19 patients with paired data. and (second line. parentheses) imputed analysis for all 20 
patients. Test statistic is given followed by p value. FC = New York Heart Association functional class; MV02 = 
maximal estimated oxygen consumption; other abbreviations as in Table 3. 
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identify the molecular and cellular mechanisms of this ac-
tion. 
Left ventricular ejection fraction and clinical heart failure 
have consistently proved to be strong and independent 
predictors of subsequent mortality in natural history studies 
of patients with cardiac disease. It is therefore hoped (but 
must be demonstrated) that the functional improvement 
noted after bucindolol therapy will also correlate with im-
proved long-term survival. 
Complex effects of beta-blockade on exercise performance. 
Some (15,35) but not other (14,17,18) studies have reported 
improvement of maximal exercise tolerance in patients with 
idiopathic dilated cardiomyopathy treated with beta-
blockers (usually metoprolol). However, beta-blocker ther-
apy in other groups, such as normal subjects and hyperten-
sive patients, has generally been associated with unchanged 
or reduced exercise tolerance, particularly for nonselective 
beta-blockers (36). Furthermore, bucindolol is 10 times more 
potent than metoprolol for beta l receptor blockade in exper-
imental studies, and also blocks beta2 receptors (30). The 
lack of change in maximal exercise performance in patients 
with idiopathic dilated cardiomyopathy treated with bucin-
dolol compared with the improvement in performance pre-
viously reported for metoprolol may thus be due to large 
differences in the amount of beta-blockade and the degree of 
exercise suppression of heart rate achieved in these studies. 
Because patients indicated by their symptom score (31) and 
functional class that they showed improved functional ca-
pacity during daily living, tests of submaximal performance 
should be evaluated in future trials. Also, smaller doses of 
bucindolol may be found to be effective in preserving left 
ventricular function and yet allow for greater maximal 
exercise performance than that we observed. 
Study limitations and comparisons. The long-term portion 
of our study possesses certain limitations of baseline con-
trolled trials. The natural history of the untreated disease is 
not assessed between 3 months and 2 years because we 
discontinued the parallel placebo group after 3 months. 
(Because bucindolol showed a clear advantage after 3 
months [31], continuation of placebo beyond 3 months 
would have raised serious ethical concerns for our study 
cohort.) However, because the short-term trial showed 
active therapy to be significantly better than placebo, and 
because the disease is known from other natural history 
studies to have a progressive and deteriorating course (2-4), 
it may be reasonable to suppose that the late benefit was 
treatment related. Specifically, the Veterans Administration 
Heart Failure Trial (V-HeFT) assessed the natural history of 
heart failure in patients whose functional status was roughly 
similar to that of our study group (8). Their cohort was 
somewhat older (58 vs. 50 years), but ejection fraction (30% 
vs. 25%) and maximal exercise duration (9.8 vs. 9.3 min) 
were slightly better at baseline. The mortality rate at 2 years 
in V-HeFT was 34.3% during placebo therapy (n = 273) and 
25.6% during vasodilator therapy (hydralazine/nitrates, n = 
186). In comparison, 2 year outcome during bucindolol 
lACC Vol. 17, No.6 
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therapy was favorable, with no deaths and a 15% rate of 
deterioration (3 of 20) during long-term therapy or a 23% (5 of 
22) rate of intolerance to drug or deterioration during combined 
initial «3 months) and long-term study experience. 
The results presented do not include data for one patient 
who dropped out before long-term evaluation was possible; 
results for two others not believed to be optimally respond-
ing could be included to the time they were withdrawn for 
transplantation but not to the end offollow-up. However, an 
imputed analysis, including these three at the common time 
end point and assuming a "worst case" response, continued 
to support an overall beneficial effect of therapy on ejection 
fraction and functional class for the group as a whole. 
Further studies with larger numbers of subjects are neces-
sary to confirm the benefits of beta-blockade on major morbid-
ity and mortality and to assess whether potential benefits are 
restricted to patients with heart failure caused by idiopathic 
dilated cardiomyopathy or can also be extended to patients 
with heart failure due to ischemic heart disease and other 
causes. The patients enrolled in this study were clinically stable 
and in functional classes II and III at entry. The favorable 
safety and tolerance we observed may not apply to patients in 
unstable condition or those in functional class IV. Whether the 
beneficial effects we noted for bucindolol are qualitatively or 
quantitatively distinct or also apply to other beta-blockers is 
not addressed by this study and must be determined by future 
comparative trials. Despite these reservations, the present 
study adds to a growing body of evidence suggesting that 
beta-blocker therapy may provide short- and long-term benefit 
(15,31,35,37) in these patients. 
Conclusions.· In this study, the beneficial effects of beta-
blockade with bucindolol, observed during a short-term 
placebo-controlled study, persisted during long-term ther-
apy. Over a mean follow-up interval of 1.5 to 2 years, the 
benefit (with respect to left ventricular ejection fraction and 
functional class) was found to be maintained or improved in 
the majority of patients. Exercise performance was also 
maintained but was not further augmented. Three patients 
showed deterioration in function during follow-up, requiring 
alternative therapies. However, the overall response, when 
compared with our short-term placebo experience and with 
other short- and long-term experiences (15,35), suggests that 
beta-blocker/vasodilator therapy with bucindolol is a prom-
ising new approach to maintaining and improving functional 
capacity in many patients with idiopathic dilated cardiomy-
opathy over a period of at least 2 years. 
We thank Shari Bailey for typing the manuscript and Ronald L. Menlove, PhD 
for statistical assistance. 
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